Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab dose/combo comparison in second-line advanced NSCLC
2017-003684-35Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cemiplimab and ipilimumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Objective response rate in PD-L1 <50% population. Started Apr 2018; status: completed.
02
Drugs
cemiplimabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-003684-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003684-35.